Evidence map›Paper›PMID 30617864›Full record

ReviewNeurochemical research2019

Nrf2/ARE Pathway as a Therapeutic Target for the Treatment of Parkinson Diseases.

Artem P Gureev, Vasily N Popov

Abstract readReview
PubMed Publisher
In one paragraph

Review in Neurochemical research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
3.2field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 64 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Dual Role of YY1 in HPV Life Cycle and Cervical Cancer Development.International journal of molecular sciences · 2022
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Artem P GureevDepartment of Genetics, Cytology and Bioengineering, Voronezh State University, Voronezh, Russia. gureev@bio.vsu.ru.ORCID http://orcid.org/0000-0003-3562-5329
Vasily N PopovDepartment of Genetics, Cytology and Bioengineering, Voronezh State University, Voronezh, Russia.ORCID http://orcid.org/0000-0003-1294-8686
Voronezh State University · RU

Funding

Ministry of Education and Science of the Russian Federation State Assessment N 6.4656.2017/8.9President Grant for Support of Leading Scientific School Agreement 14.Z57.18.3451-NShRussian Foundation for Basic Research 19-04-00850 ?
6 · The paper itself

Abstract

Instead of the progress in the understanding of etiology of Parkinson's disease (PD), effective methods to prevent the progression of the disease have not been developed and only symptomatic treatment is currently possible. One of possible pathways to slow the progression of the disease is protection of dopaminergic neurons by maintaining mitochondrial quality control in neuron cells. Recent studies showed that the most promising target for pharmacological effects on mitochondria is the Nrf2/ARE signaling cascade. It participates in the maintenance of mitochondrial homeostasis, which is provided by an optimal ratio in the processes of mitochondrial biogenesis and mitophagy, as well as the optimal ratio of ROS production and ROS scavenging. Nrf2 activators are capable of modulating these processes, maintaining mitochondrial homeostasis in neurons. In addition, Nrf2 can synergistically interact with other transcription factors, for example, PGC-1a in the regulation of mitochondrial biogenesis and YY1 with the increase of antioxidant defense. All this makes Nrf2 an optimal target for drugs that could support the mitochondrial quality control, which, in combination with antioxidant protection, can significantly slow down the pathogenesis of PD. Some of these compounds have undergone laboratory studies and are at the stage of clinical trials now.

Indexed as

AnimalsDopaminergic NeuronsHumansMitochondriaMitophagyNF-E2-Related Factor 2Parkinson DiseaseSignal TransductionUbiquitin-Protein LigasesNF-E2-Related Factor 2Ubiquitin-Protein LigasesMitochondrial biogenesisMitochondrial quality controlMitophagyNrf2Parkinson disease

Identifiers

PMID30617864
OpenAlexW2911118120

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.